Elquis Castillo, MD
Medical Oncology · Gadsden, ALNPI 1609890474
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Mckesson Specialty Care Distribution, LLC at 55.9% of the total. Reporting peaked in 2019 at $1,059 and has fallen 65.7% since, to $363 in 2025. That places this record below the midpoint for medical oncology clinicians in AL, where the typical reported total is $5,924.
Across 33 payments — averaging $76.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mckesson Specialty Care Distribution, LLC$1K
- US Oncology Corporate, Inc.$815
- Intuitive Surgical$133
- Onmark, Inc.$122
- Boston Scientific$17
- Helsinn Therapeutics (U.S.), Inc.$15
- plus $12 from 1 others
What the payments were for
- Food & beverage$2,49799%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mckesson Specialty Care Distribution, LLC | 18 | $1,410 |
| US Oncology Corporate, Inc. | 10 | $815 |
| Intuitive Surgical | 1 | $133 |
| Onmark, Inc. | 1 | $122 |
| Boston Scientific | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,523 in reported general payments places this provider in the 30th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 110 | $1,355,596 |
| JakafiRuxolitinib Phosphate | 78 | $1,130,951 |
| BrukinsaZanubrutinib | 67 | $983,018 |
| ImbruvicaIbrutinib | 61 | $808,777 |
| Lenalidomide | 57 | $659,664 |
| IbrancePalbociclib | 33 | $502,629 |
| RevlimidLenalidomide | 29 | $477,779 |
| PomalystPomalidomide | 20 | $453,911 |
| CalquenceAcalabrutinib Maleate | 25 | $377,166 |
| LenvimaLenvatinib Mesylate | 15 | $364,626 |
| XtandiEnzalutamide | 23 | $329,074 |
| LynparzaOlaparib | 32 | $302,505 |
| VerzenioAbemaciclib | 17 | $238,635 |
| GleevecImatinib Mesylate | 18 | $233,503 |
| VenclextaVenetoclax | 11 | $167,148 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Gadsden
- Dinesh ParmarGadsden$2K
- Joelle HamiltonHomewood$361K
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Johnny NacillaCullman$23K
- Michael GarciaJasper$23K
- John WaplesHuntsville$19K
- Susan BostickTuscaloosa$17K
- Brittany CaseDaphne$17K
- Charles LattuadaAnniston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.